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Abstract
Background: BCL-2 (B-cell leukemia/lymphoma 2) gene has been demonstrated to be associated with breast
cancer development and a single nucleotide polymorphism (SNP; -938C > A) has been identified recently. To
investigate whether this polymorphism functions as a modifier of breast cancer development, we analyzed the
distribution of genotype frequency, as well as the association of genotype with clinicopathological characteristics.
Furthermore, we also studied the effects of this SNP on Bcl-2 expression in vitro.
Methods: We genotyped the BCL-2 (-938C > A) in 114 patients and 107 controls, and analyzed the estrogen
receptor (ER), progestogen receptor (PR), C-erbB2 and Ki67 status with immunohistochemistry (IHC). Different Bcl-2
protein levels in breast cancer cell lines were determined using western blot. Logistic regression model was
applied in statistical analysis.
Results: We found that homozygous AA genotype was associated with an increased risk (AA vs AC+CC) by 2.37-
fold for breast cancer development and significant association was observed between nodal status and different
genotypes of BCL-2 (-938C > A) (p = 0.014). AA genotype was more likely to develop into lobular breast cancer
(p = 0.036). The result of western blot analysis indicated that allele A was associated with the lower level of Bcl-2
expression in breast cancer cell lines.
Conclusions: AA genotype of BCL-2 (-938C > A) is associated with susceptibility of breast cancer, and this
genotype is only associated with the nodal status and pathological diagnosis of breast cancer. The polymorphism
has an effect on Bcl-2 expression but needs further investigation.
Background
Breast cancer has become the most common female
malignancy around the world. Each year, there’re over
one million women diagnosed with breast cancer, with
approximately 400,000 deaths [1]. Like other carcino-
mas, breast cancer occurs based on an interaction
between genetic heterogeneity and the environment. It
has been reported that an accumulation of genetic var-
iants is involved in the process of breast carcinogenesis
[2]. Among these genetic variants, many of them play
roles in apoptosis or cellular proliferation, since the bal-
ance between the two decides which direction to go:
normal mammary development or carcinogenesis of the
mammary gland [3].
Apoptosis is a highly programmed cell death, and it can
be achieved by two major pathways: death-receptor path-
way and mitochondrial pathway [4]. Bcl-2 family, as the
most important regulator in the mitochondrial pathway,
contains both anti-apoptotic proteins such as Bcl-2 and
Bcl-xL and pro-apoptotic proteins such as Bax, Bad and
Bak [5]. Although Bcl-2 is an oncogenic protein, the asso-
ciation between its expression and patient survival result
is quite conflicting and seems tissue-specific. Increased
Bcl-2 expression is associated with poor survival in B-cell
chronic lymphocytic leukemia (CLL), prostate cancer and
urinary tract transitional cell cancer [6-9]; while its high
expression is associated to favorable outcome in colorec-
tal cancer, breast cancer, non-small-cell lung cancer,
renal cancer and head and neck cancer [10-15].
BCL-2 (B-cell leukemia/lymphoma 2) gene, located at
18q21.3 [16], consists of three exons and two promoters
(P1 and P2), which have different functions. The second
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any medium, provided the original work is properly cited.promoter, P2, is located 1,400 bp upstream of the transla-
tion initiation site and functions as a negative regulatory
element to the P1 promoter [17,18]. Park et al. investi-
gated the genetic variants of BCL-2 genes by sequencing
the 24 Korean DNA samples and identified a novel single
nucleotide polymorphism (SNP; -938C > A) in P2[19].
According to the findings from Nuckel et al., the -938C
allele is associated with significantly increased P2 activity
and binding of nuclear proteins compared with the A
allele. Due to the negatively regulatory function of P2,
Bcl-2 protein expression was significantly decreased in B
cells derived from CLL patients carrying the -938CC gen-
otype [20]. However, Majid et al. reported no association
of Bcl-2 protein expression level with the promoter SNP
or any clinical or laboratory parameters [21]. On the
other hand, it has been suggested that the (-938C > A)
polymorphism could serve as a survival prognosticator as
well as high-risk indicator within the lymph node-
negative breast cancer [22]. In order to investigate
whether BCL-2 (-938C > A) genotype can serve as a sus-
ceptible and/or progressive factor in breast cancer, we
analyzed the distribution of genotype frequency among
breast cancer cases and controls, as well as the associa-
tion of genotype with clinicopathological characteristics.
In addition, we also chose 4 breast cancer cell lines to
investigate the association between this polymorphism
and Bcl-2 expression in vitro.
Methods
Patients and Samples
The study involved 114 patients diagnosed with breast
cancer in Qilu Hospital (Shandong, China) between
September 2008 and April 2010. All the malignant cases
were classified and assessed according to the WHO clas-
sification of tumor of the breast. Among all the patients,
7 had lobular carcinoma, 87 had tubular carcinoma and
2 0s u f f e r e df r o mo t h e rm a l i g n a n tt y p e s .T h es i z eo ft h e
primary tumor was defined as the largest tumor dia-
meter (cm) reported by pathologists after surgical exci-
sion. To investigate whether BCL-2 -938 SNP is a
susceptible biomarker, 107 healthy women were
involved as control group in this study. The average age
of cases and controls are 49.1 ± 5.51 and 47.8 ± 11.4
years separately, and the Student’s t test showed no sig-
nificant difference between the two groups (p =0 . 3 7 4 ) .
For both patient and control group, 1.5 ml whole blood
sample was extracted from each participant and stored
at -80°C. Written informed consent was signed by each
subject and the study design was approved by the Ethi-
cal Committee of Shandong University.
Cell culture
Breast cancer cell lines (MCF-7, MDA-MB-453, MDA-
MB-468 and T-47 D cell lines) were all obtained from
American Type Culture Collection (ATCC, Manassas,
VA, USA), and routinely cultured in appropriate med-
ium supplemented with 10% FBS (Haoyang, Tianjin,
China), 100 U/ml penicillin, and 100 μg/ml streptomy-
cin, under the condition of 5% CO2 at 37°C.
DNA extraction
DNA from both whole blood cells and cultured breast
cancer cells was extracted with TIANamp Genomic
DNA Kit (Tiangen, Beijing, China), following the manu-
facturer’s instructions. DNA concentration and purity of
each sample were measured by ultraviolet spectrophot-
ometer (GE Healthcare, Piscataway, NJ, USA). DNA
samples were routinely stored at -20°C.
PCR-restriction fragment length polymorphism analysis of
BCL2 -938 polymorphism
Genotyping of the SNP -938C > A polymorphism was
determined by PCR-restriction fragment length poly-
morphism (PCR-RFLP) method. Primers were designed
according to the sequence of rs2279115 as follows: for-
ward primer 5’-TTATCCAGCAGCTTTTCGG-3’ and
reverse primer 5’-GGCGGCAGATGAATTACAA-3’.I n
each 25 μl reaction, 1 μl genomic DNA (100 ng/μl) was
amplified by 1.25 U EasyTaq DNA polymerase (Transgen,
Beijing, China) with 2 μl of 2.5 mM dNTPs and 0.5 μlo f
each primer. The PCR conditions were set as follows: 94°C
for 5 min, 35 cycles of 94°C for 30 s, 60°C for 30 s, and
72°C for 30 s and a final extension step of 72°C for 10 min.
After PCR reaction, 10 μl product from each sample
was digested by BccI Enzyme (NEB, Beijing, China) for
2 hours. After electrophoresis on 3% ethidium bromide
added agarose gel, photographs were taken under ultra-
violet light transilluminator. To confirm our results of
genotyping, several PCR products were randomly picked
for sequencing.
Immunohistochemistry (IHC) and evaluation of IHC
staining
To evaluate the association between BCL-2 SNP-938C >
A and clinicopathological parameters (estrogen receptor
(ER), progestogen receptor (PR), C-erbB2 and Ki67), tis-
sue microarrays were made and stained as described
previously[23]. An already known positive case was
included as the positive control, while the primary anti-
body was replaced with non-immune mouse serum as
the negative control. Evaluation of the IHC staining
results was proceeded by pathologists without knowing
the Bcl-2 -938C > A genotypes. The tumor was scored
positive for ER and PR when ≥10% of the tumor cells
on the slide irrespective of the staining intensity.
C-erbB2 was evaluated according to the DAKO score;
complete membranous staining observed in ≥10% of
tumor cells (DAKO score 2+ and 3+) was defined as
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positive stained nuclear indicated a highly proliferative
activity of Ki67.
Western-blot analysis of Bcl-2 expression in breast cancer
cell lines
Breast cancer cell lines were routinely cultured and the
total protein of each cell lines was collected with RIPA
lysis buffer (Sigma, St Louis, MO, USA) in the presence
of protease inhibitors. Briefly, 100 μgo fp r o t e i nw e r e
loaded onto 12% SDS-PAGE gels and transferred to a
PVDF membrane with a semi-dry blotting apparatus
(Bio-Rad, Hercules, CA, USA). After blocking with 5%
non-fat milk, the membrane was incubated overnight at
4°C with primary anti-Bcl-2 (1:250; Carpinteria, CA,
USA), followed by binding with the secondary antibody.
b-actin was used as endogenous control. The expression
of each protein was quantified as the densitometry value
analyzed by ImageJ. The figure shown is representative
of three independent experiments.
Statistical Analysis
T h eg e n o t y p ea n da l l e l ef r e q u e n c yo fBCL-2 SNP938
were tested using the public statistical web-tool http://
www.oege.org/software/hwe-mr-calc.shtml for Hardy-
Weinberg equilibrium (HWE). P-value > 0.05 was con-
s i d e r e dn o td e v i a t ef r o mt h ee q u i l i b r i u m .L o g i s t i c
regression model was carried out to analyze the distri-
bution of BCL-2 SNP938 polymorphism between case
and control group and the clinicopathological character-
istics of breast cancer. All statistical tests were consid-
ered significant with a level of p ≤ 0.05. Odds ratios
(OR) adjusted for age were calculated. All statistical ana-
lyses in our study were carried out with SPSS Statistics
17.0 (SPSS Inc. Chicago, Illinois, USA).
Results
A) genotype distribution",1,0,1,0,0pc,0pc,0pc,0pc>The
BCL-2 (-938C > A) genotype distribution
The breast cancer patients and healthy controls were all
Chinese mainland women and we didn’t find statistically
significant difference between the two groups in the
matching characteristic. Chi-square test was used to
determine whether the subjects met the Hardy-Wein-
berg equilibrium. We confirmed that both case and con-
trol groups were compatible with the HWE, for in case
and control groups the c
2 value was 0.11 and 1.91
respectively, both p > 0.05.
As shown in Table 1, in the logistic regression model,
BCL-2 SNP938 variant genotype CC was associated with
a decreased risk for breast cancer by 0.40-fold compared
with the homozygote AA. Additionally, genotype AA
was associated with an increased risk for breast cancer
by 2.37-fold compared with the combined genotype AC
+CC. Several samples from cases were randomly chosen
to show the result of genotyping (Figure 1), and the gen-
otype distribution of BCL-2 SNP938 polymorphism
between case and control group was shown in Table 1.
Our data indicated that the homozygous AA genotype
may be a susceptible genotype for breast cancer devel-
opment and may increase the risk of breast cancer
among Chinese women.
A) polymorphism and known clinicopathological
variables",1,0,1,0,0pc,0pc,0pc,0pc>Association between
BCL-2 (-938C > A) polymorphism and known
clinicopathological variables
Table 2 listed the association of AA and AC+CC geno-
types with clinicopathological characteristics, including
age at diagnosis, pathological diagnosis, tumor size
and grade, nodal metastasis and status of several biologi-
cal markers. The AA genotype and the occurrence
of lobular breast cancer showed a strong association
(p = 0.036). Furthermore, the association of different
genotypes with the lymph nodal status was significant
(p = 0.014). However, we found no association of the
polymorphism with age at diagnosis, tumor size and
grade. Regarding to the biological markers, which can
predict disease prognosis and treatment outcomes, the
genotypes were similarly distributed irrespective of the
status of ER, PR, erbB2 and Ki67, neither do the recep-
tor status or triple-negative breast cancer. Thus, the
BCL-2 (-938C > A) polymorphism may be an indicator
of lymph nodal metastasis in female breast cancer.
Table 1 The BCL-2 (-938C > A) genotype distribution in
patients and controls
Genotype No. of subjects (%) Non-adjusted
b Adjusted
c
Case
a Control
a p value OR p value OR
AA 19(16.7) 8(7.5) 1.00 1.00
AC 53(46.5) 53(49.5) 0.062 0.42 0.081 0.44
CC 42(36.8) 46(43.0) 0.043 0.38 0.054 0.40
AC+CC 95(83.3) 99(92.5) 1.00 1.00
AA 19(16.7) 8(7.5) 0.042 2.47 0.055 2.37
AC+AA 72(63.2) 61(57.0) 1.00 1.00
CC 42(36.8) 46(43.0) 0.351 0.77 0.358 0.77
AA+CC 61(53.5) 54(50.5) 1.00 1.00
AC 53(46.5) 53(49.5) 0.651 0.89 0.711 0.90
All 114 107
a The c
2 for HWE of case and control group is 0.11 and 1.91 respectively
(both p > 0.05).
b Logistic regression model, non-adjusted.
c Logistic regression model, adjusted for diagnostic age.
All statistical tests were two-sided with a significance level of p ≤ 0.05.
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and Bcl-2 expression in vitro
We further investigated the possible linkage of BCL-2
(-938C > A) polymorphism with Bcl-2 expression level in
vitro; we tested the genotypes of the polymorphism and
Bcl-2 expression in 4 breast cancer cell lines. Figure 2
showed the result of genotyping and western blot of the
4 breast cancer cell lines (MCF-7, MDA-MB-453, MDA-
MB-468 and T-47D). From the result, we can identify an
association that CC genotype correlated with high Bcl-2
expression and AA genotype displayed an intermediate
level, while AC genotype correlated with the lowest
expression. The ratio of Bcl-2/actin was almost 5-fold
higher comparing CC genotype (1.00 ± 0.11) with AC
genotype (0.18 ± 0.10; p = 0.0006; Student’s t test),
whereas no significant effect was found when comparing
AA genotype (0.24 ± 0.05) to AC genotype (0.18 ± 0.10;
p = 0.372; Student’s t test). Overall, BCL-2 (-938C > A)
polymorphism showed a contribution to Bcl-2 expres-
sion, namely allele A was associated with lower level of
Bcl-2 expression and vice versa.
Discussion
Anti-apoptotic BCL-2 gene plays an important role in
regulation of apoptosis and triggering cell cycle arrest.
Due to its role in CLL development, many studies which
focused on its function and variants were carried out in
leukemia previously. The BCL-2 (-938C > A) polymorph-
ism, which was first identified by Park and colleagues
[19], has attracted a lot of attention recently; the result of
these studies[20,21,24-26] in CLL patients appeared in
great controversial and no agreement has been reached.
However, studies carried out in solid tumors showed a
more consistent result [14,15,22,27,28], indicating BCL-2
Figure 1 Bcl-2 (-938C > A) genotyping results. BCL-2 (-938C > A) polymorphism genotyping with PCR-RFLP and DNA sequencing. Several
samples from cancer group were chosen randomly to show the PCR-RFLP results, and DNA sequencing was used to confirm our result of
genotyping. Undigested 252 bp products represent CC genotype, and totally digested 154 and 98 bp products represent AA genotype; AC
heterozygous genotype showed both the undigested 252 bp band and digested 154 and 98 bp bands.
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cific way. Since Bcl-2 protein has been reported to contri-
bute much to breast malignancy development (or
progression), we conducted this study to investigate
whether this polymorphism functioned as a modifier of
breast cancer development.
In our study, we found that homozygous AA genotype
may be a susceptible genotype for breast cancer devel-
opment and this genotype is associated with the patho-
logical diagnosis and nodal status of breast cancer. In
addition, we investigated the effect of this polymorphism
on Bcl-2 expression in vitro and found that allele A was
associated with the lower level of Bcl-2 expression.
As indicated in previous literatures, this polymorphism
was located in the second promoter of the BCL-2 gene,
which worked as a negative modulator on the first pro-
moter and subsequently, BCL-2 gene expression [18].
According to the study of Nuckel et al., the presence of
AA genotype was associated with decreased activity of
P2 and increased Bcl-2 protein expression and was
demonstrated as an unfavorable genetic marker in
patients with B-CLL [20]. In contrast, we showed that
allele A was associated with low Bcl-2 expression in
breast cancer cell lines and AA genotype is in positive
relation to breast cancer susceptibility. This result can
partly explain the reason why high Bcl-2 expression is
Table 2 Relationship between BCL-2 (-938C > A) polymorphism and known clinicopathological variables
Clinicopathological Variables All Genotype (%) Adjusted
a
AA AC+CC p value OR
Age
≤ 40 21(18.9) 3(14.3) 18(85.7) 1.00
> 40 90(81.1) 15(16.7) 75(83.3) 0.790 1.20
Pathological diagnosis
Ductal 87(76.3) 14(16.1) 73(83.9) 1.00
Lobular 7(6.1) 3(42.9) 4(57.1) 0.036 6.42
Others 20(17.6) 2(10.0) 18(90.0) 0.605 0.66
Tumor size(cm)
≤ 2 50(53.2) 9(18.0) 41(82.0) 1.00
> 2 44(46.8) 9(20.4) 35(79.6) 0.704 1.23
Grade
I, II 59(79.7) 10(16.9) 49(83.1) 1.00
III 15(20.3) 2(13.3) 13(86.7) 0.725 0.74
Positive lymph node
0 34(44.7) 3(8.8) 31(91.2) 1.00
1-3 25(32.9) 3(12.0) 22(88.0) 0.672 1.44
≥ 4 17(22.4) 7(41.2) 10(58.8) 0.014 6.95
ER
Negative 28(26.9) 6(21.4) 22(78.6) 1.00
Positive 76(73.1) 12(15.8) 64(84.2) 0.493 0.68
PR
Negative 37(35.9) 8(21.6) 29(78.4) 1.00
Positive 66(64.1) 10(15.2) 56(84.8) 0.688 0.80
Receptor status
Negative 26(25.2) 6(23.1) 20(76.9) 1.00
Positive 77(74.8) 12(15.6) 65(84.4) 0.115 3.06
c-erbB2
Negative 73(70.2) 13(17.8) 60(82.2) 1.00
Positive 31(29.8) 5(16.1) 26(83.9) 0.936 1.05
Triple-negative
No 87(84.5) 14(16.1) 73(83.9) 1.00
Yes 16(15.5) 4(25.0) 12(75.0) 0.444 1.67
Ki67
Negative 59(58.4) 10(16.9) 49(83.1) 0.875 1.00
Positive 42(41.6) 7(16.7) 35(83.3) 1.09
aLogistic regression model adjusted for diagnostic age.
All statistical tests were two-sided with a significance level of p ≤ 0.05.
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[12,29,30]. The different results in CLL and breast
cancer may be determined by the balance between the
dual function of Bcl-2 protein[31]. On one hand it plays
an important role as an oncogene to inhibit apoptosis;
on the other hand, it can initiate cell cycle arrest at G0
stage [32] and cause growth inhibitory effects similar to
those of p53 [33]. Nevertheless, a recent study by Bach-
mann et al. reported no significant association was
observed between Bcl-2 expression status and BCL-2
(-938C > A) polymorphism (p = 0.485) [22]. Therefore,
the association of BCL-2 (-938C > A) polymorphism
with Bcl-2 expression in primary tumor should be stu-
died in a larger sample size and the involved molecular
mechanisms need further investigation. Additionally, it
was reported that Bcl-2 high expression contributed to a
series of cytotoxic drugs resistance [34]. Thus, we can
also investigate whether the BCL-2 (-938C > A) poly-
morphism has an effect on chemotherapy resistance in
the future work.
Conclusions
In summary, we can conclude that AA genotype of
BCL-2 (-938C > A) may be one susceptible genotype for
breast cancer, and this genotype is associated with the
nodal status of breast cancer. Since Bcl-2 protein has
been demonstrated to be correlated with treatment out-
comes and prognosis of breast cancer, it is of great sig-
nificance to find the function pattern of this
polymorphism and the possible association with Bcl-2
expression. Further research is necessary to elucidate
whether BCL-2 (-938C > A) polymorphism can serve as
a prognostic biomarker for breast cancer patients.
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